A pioneering new course developed and delivered by experts in
industry and aimed at professionals working in the pharmaceutical
and healthcare sectors, is being launched at De Montfort University
Leicester (DMU).
The online Quality by Design (QbD) course is an innovative
work-based learning programme being taught by experts from leading
pharmaceutical and healthcare companies including AstraZeneca,
Pfizer, GlaxoSmithKline and Bristol-Myers Squibb, and supported by
the Pharmaceutical Technologies Research Group at DMU.
'Quality by design' is a scientific approach which has been
developed to advance product and process quality in industry.
The new course is suitable for professionals working in
pharmaceutical companies, contract manufacturing and consumer
health.
It will allow them to gain the knowledge, skills and experience
in this rapidly developing area of pharmaceutical development and
manufacturing. It will also provide the tools and techniques to
start using a 'quality by design' approach.
A free industry event to launch the course is being held at DMU
on 15 March from 4:30pm.
Keynote speeches will be delivered by: Mike Hannay, medicines
development vice-president at AstraZeneca; Martin Owen, API quality
by design leader specialising in understanding uncertainty at
GlaxoSmithKline and Roger Weaver; research fellow, co-development
right first time program office at Pfizer.
The event will provide a unique opportunity to learn more about
the course and network with senior people in the pharmaceutical
industry.
To find out more information about the course or to book a place
at the event visit www.dmu.ac.uk/qbd
Walkiria Schlindwein, QbD module leader at DMU, said: "This
innovative course is specifically designed to be flexible for
businesses and can be studied in its entirety or as separate
modules. Expert practitioners from 14 companies and consultancies
are involved in the course and all have hands-on 'quality by
design' experience."
Mike Hannay, from AstraZeneca, said: "'Quality by design' is at
the very heart of leading-edge pharmaceutical development. The
development of such a high quality course, delivered through an
innovative medium, will significantly help today's and tomorrow's
scientists build their capabilities in delivering high quality
innovative medicines for patients."
Martin Owen, from GlaxoSmithKline, said: "De Montfort
University's programme is a bold vision of collaborative creativity
- bringing together a decentralised group of industrialists,
consultants and academics to form a powerful crowd to drive a
holistic understanding of 'quality by design'."
Vince McCurdy, from Pfizer, said: "This course is a unique
integration of current knowledge on 'quality by design' from a
group of leading experts in the pharmaceutical industry. The course
will be an excellent training opportunity for those less familiar
with 'quality by design' and provide those more experienced,
suggestions on how to enhance their program."